Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment

NCT06663787 is registered in ClinicalTrials.gov with Nagoya City University as lead sponsor.

NCT NCT06663787
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06663787 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment
Lead sponsor
Nagoya City University
Phase
Observational
Overall status
Active, not recruiting
Start date
April 1, 2024
Completion date
December 31, 2026
Enrollment
50 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, metastatic, her2 + breast cancer